Advertisement
GNLX vs IMRX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GNLX is a Hold and IMRX is a Buy.
GNLX's Indicator enters downward trend
The Aroon Indicator for GNLX entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 191 similar instances where the Aroon Indicator formed such a pattern. In 179 of the 191 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GNLX as a result. In 65 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for GNLX turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 33 similar instances when the indicator turned negative. In 28 of the 33 cases the stock turned lower in the days that followed. This puts the odds of success at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GNLX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GNLX's RSI Oscillator exited the oversold zone, 23 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 55 cases where GNLX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +13.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where GNLX advanced for three days, in 174 of 201 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
GNLX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. GNLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.504) is normal, around the industry mean (3.498). P/E Ratio (-2.279) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. GNLX's P/S Ratio (10000.000) is very high in comparison to the industry average of (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GNLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
IMRX in upward trend: price expected to rise as it breaks its lower Bollinger Band on November 05, 2026
IMRX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 37 cases where IMRX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where IMRX's RSI Indicator exited the oversold zone, 23 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 79%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 48 of 59 cases where IMRX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for IMRX just turned positive on October 20, 2026. Looking at past instances where IMRX's MACD turned positive, the stock continued to rise in 34 of 40 cases over the following month. The odds of a continued upward trend are 85%.
Following a +7.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where IMRX advanced for three days, in 220 of 249 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMRX as a result. In 82 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMRX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IMRX entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. IMRX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.248) is normal, around the industry mean (3.498). P/E Ratio (-3.957) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMRX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
| GNLX | IMRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 79% |
| Stochastic ODDS (%) | 2 days ago 87% | 2 days ago 81% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 90% |
| Advances ODDS (%) | 4 days ago 87% | 9 days ago 88% |
| Declines ODDS (%) | 2 days ago 86% | 11 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 90% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GNLX’s FA Score shows that 1 FA rating(s) are green while IMRX’s FA Score has 1 green FA rating(s).
- GNLX’s FA Score: 1 green, 4 red.
- IMRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GNLX’s TA Score shows that 4 TA indicator(s) are bullish while IMRX’s TA Score has 5 bullish TA indicator(s).
- GNLX’s TA Score: 4 bullish, 4 bearish.
- IMRX’s TA Score: 5 bullish, 3 bearish.
Price Growth
GNLX (@Biotechnology) experienced а -4.08% price change this week, while IMRX (@Biotechnology) price change was +0.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
IMRX is expected to report earnings on Mar 11, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
GNLX and
Correlation & Price change
A.I.dvisor indicates that over the last year, GNLX has been loosely correlated with MGTX. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if GNLX jumps, then MGTX could also see price increases.
| Ticker / NAME | Correlation To GNLX | 1D Price Change % | ||
|---|---|---|---|---|
| GNLX | 100% | -3.59% | ||
| MGTX - GNLX | 38% Loosely correlated | +0.62% | ||
| RCUS - GNLX | 37% Loosely correlated | +0.70% | ||
| BCYC - GNLX | 37% Loosely correlated | N/A | ||
| IMRX - GNLX | 37% Loosely correlated | -1.56% | ||
| VIR - GNLX | 36% Loosely correlated | -0.15% | ||
More | ||||
IMRX and
Correlation & Price change
A.I.dvisor indicates that over the last year, IMRX has been loosely correlated with ACRV. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if IMRX jumps, then ACRV could also see price increases.
| Ticker / NAME | Correlation To IMRX | 1D Price Change % | ||
|---|---|---|---|---|
| IMRX | 100% | -1.56% | ||
| ACRV - IMRX | 52% Loosely correlated | N/A | ||
| CRMD - IMRX | 50% Loosely correlated | -1.30% | ||
| JSPR - IMRX | 40% Loosely correlated | +0.07% | ||
| LXEO - IMRX | 40% Loosely correlated | +0.33% | ||
| GHRS - IMRX | 39% Loosely correlated | -1.58% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IGA | 10.15 | 0.09 | +0.89% |
| Voya Global Advantage AND Premium Opportunity Fund | |||
| BRAZ | 27.64 | 0.21 | +0.76% |
| Global X Brazil Active ETF (BRAZ) | |||
| ROSC | 55.55 | 0.18 | +0.32% |
| Hartford Multifactor Small Cap ETF (ROSC) | |||
| ICLO | 25.58 | -0.01 | -0.04% |
| Invesco AAA CLO Floating Rate Note ETF (ICLO) | |||
| SPTS | 28.69 | -0.02 | -0.07% |
| State Street SPDR Portfolio Short Term Treasury ETF (SPTS) | |||